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Conclusion: Patients with usually stable international normalized ra-
tios (INRs) receiving warfarin who experience a significant subtherapeutic
INR value have a low risk of thromboembolism in the ensuing 90 days.
Summary: Optimal use of warfarin is hampered by unpredictable
pharmacokinetics. In specialized anticoagulation clinics, about 40% of INRs
fall outside the target therapeutic range, and most of these abnormal INR
values are below the target range (Chest 2005;127:1515-22). The authors
conducted a retrospective longitudinal investigation to quantify risk associ-
ated with isolated subtherapeutic anticoagulation. The study was conducted
at Kaiser Permanente Colorado. Anticoagulation services were provided by
a specialized clinical pharmacy anticoagulation service.
A total of 2597 adult patients received warfarin from January 1998 to
December 2005. Of these, 1080 who were classified in the low INR cohort
were matched with 1517 patients with therapeutic INRs. Stable therapeutic
anticoagulation status was defined as two INR values measured at least 2weeks apart within or above the therapeutic range. The low INR cohort was
described as patients with an INR value of 0.5 units below therapeutic
range. The primary outcome variable was anticoagulation-related thrombo-
embolism during the 90 days after the index INR. Secondary outcomes were
times to first occurrence of anticoagulation-related complications (bleeding,
death, or thromboembolism) in the 90 days after the index INR.
Four thromboembolic events (0.4%) occurred in the low INR cohort
and one event (0.1%) in the therapeutic INR cohort (P .214). There were
no differences in proportions of thromboembolism, bleeding, or death
between the two groups.
Comment: This study has several strengths, including its large sample
size, carefully defined patient population, and essentially complete follow-up
in outcome assessment of the patients in this anticoagulation clinic. Al-
though not many events were documented, approximately 40% of the
patients managed in this anticoagulation clinic were in the low INR cohort.
Therefore the data therefore seem fairly strong and indicate a single low INR
value is of very little consequence in a patient with an otherwise stable
anticoagulation profile. The findings do not support bridge therapy with
heparins in patients previously stable on warfarin who have a period of
subtherapeutic anticoagulation. Of course, this was a retrospective study;
therefore, capture of outcome events may have been incomplete. Neverthe-
less, it does not appear one should not become too concerned when a
patient, who is otherwise stable on warfarin anticoagulation, presents with a
diminished INR.
